Nanyang Pukang Pharmaceutical Co., Ltd.

It has highly selective antibacterial effects on all types of Mycobacterium tuberculosis. It is the synthetic antibacterial drug with the strongest bactericidal effect among current anti-tuberculosis drugs, and has almost no effect on other bacteria. It has a strong effect on Mycobacterium tuberculosis in the growth and reproduction stage, but a weaker and slower effect on the dormant stage. Its mechanism of action may be to inhibit the synthesis of mycolic acid in sensitive bacteria and cause the cell wall to rupture.

This product belongs to the aminoglycoside antibiotics, and its antibacterial spectrum is similar to that of gentamicin. It has antibacterial effects on a variety of Gram-negative bacteria, and its antibacterial effect on Pseudomonas aeruginosa is 3 to 5 times stronger than that of gentamicin. Its mechanism of action is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins.

It is a vasodilator that can dilate coronary arteries and cerebral blood vessels, reduce myocardial oxygen consumption, improve microcirculation and resist platelet aggregation. Animal experiments have shown that: 1. The various total flavonoid compounds in Pueraria root can relax smooth muscles, while the contractile components may be substances such as choline, acetylcholine and carbazine R; 2. Pueraria root has a certain antihypertensive effect on normal and hypertensive animals; 3. Pueraria root total flavonoids and puerarin have a significant dilating effect on coronary arteries, which can dilate normal and spasmodic coronary arteries. After intravenous injection, coronary blood flow can increase by 40% and vascular resistance can be reduced by 29%; 4. Puerarin can also inhibit the release of 5-HT in platelets induced by thrombin.

This product is a semi-synthetic aminoglycoside antibiotic with strong antibacterial activity against aerobic Gram-negative bacteria, and has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa and other bacteria. It is stable to aminoglycoside acetyltransferase AAC (3) and can inhibit bacterial protein synthesis. Animal experiments show that it has low ototoxicity and nephrotoxicity.

This product is a semi-synthetic aminoglycoside antibiotic with strong antibacterial activity against aerobic Gram-negative bacteria. Its antibacterial spectrum is similar to that of gentamicin. It has good antibacterial effects on Escherichia coli, Pseudomonas aeruginosa, indole-negative and -positive Proteus, Klebsiella, Acinetobacter, Citrobacter, and some strains of Serratia and Enterobacter. It also has good antibacterial effects on Mycobacterium tuberculosis, atypical mycobacteria and Staphylococcus aureus (enzyme-producing and non-enzyme-producing strains). Other Gram-positive bacteria (including Streptococcus faecalis), anaerobic bacteria, Rickettsia, fungi and viruses are not sensitive to this product. This product is stable to aminoglycoside acetyltransferase AAC (3), so it can produce this enzyme. Strains resistant to kanamycin, gentamicin, tobramycin and sisomicin are sensitive to this product. This product can often achieve synergistic effects when used in combination with beta-lactams. The mechanism of action of this product is to bind to the 30S subunit of the bacterial ribosome and inhibit the synthesis of bacterial proteins. Animal test data indicate that this product has lower ototoxicity than gentamicin and tobramycin, and lower nephrotoxicity than gentamicin.